Your browser doesn't support javascript.
loading
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot, Philippe; Charbonnier, Aude; Cony-Makhoul, Pascale; Agape, Philippe; Nicolini, Franck E; Varet, Bruno; Gardembas, Martine; Etienne, Gabriel; Réa, Delphine; Roy, Lydia; Escoffre-Barbe, Martine; Guerci-Bresler, Agnès; Tulliez, Michel; Prost, Stéphane; Spentchian, Marc; Cayuela, Jean Michel; Reiffers, Josy; Chomel, Jean Claude; Turhan, Ali; Guilhot, Joëlle; Guilhot, François; Mahon, François-Xavier.
Affiliation
  • Rousselot P; Philippe Rousselot, Hôpital Mignot, Université Versailles Saint-Quentin-en-Yvelines, Versailles; Aude Charbonnier, Institut Paoli Calmette, Marseille; Pascale Cony-Makhoul, Hôpital d'Annecy, Pringy; Philippe Agape, Hôpital Felix Guyon-Centre Hospitalier Universitaire en France (CHU) de la Réunion, La Réunion; Franck E. Nicolini, Centre Hospitalier Lyon Sud, Pierre-Bénite; Bruno Varet, Hôpital Necker, Assistance Publique-Hopitaux de Paris (AP-HP) et Université Paris Descartes; Delphine Réa and Je
J Clin Oncol ; 32(5): 424-30, 2014 Feb 10.
Article in En | MEDLINE | ID: mdl-24323036
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Benzamides / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl / Protein Kinase Inhibitors / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: J Clin Oncol Year: 2014 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Benzamides / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl / Protein Kinase Inhibitors / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: J Clin Oncol Year: 2014 Document type: Article